In our approach, we collected data from several studies reporting the fibrosis scores from paired liver biopsy studies; many of the studies overlap with the analysis performed by Singh et al. These studies consisted of patients with biopsy confirmed NAFLD or NASH and included patients with diabetes, metabolic syndrome, hypertension, reduced insulin sensitivity, and obese and non-obese patients. This evidence concerns the gene INS and metabolic syndrome.